Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 3/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.46 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404722 | 0.84 | NLRP3 (0.46) | KCNQ2KCNQ3KCNQ4KCNQ5NLRP3 | |
| Hydrochloric Acid SCHEMBL10882348 | 0.82 | KCNQ3 (0.37) | KCNQ2KCNQ3KCNQ4KCNQ5NLRP3 | |
| SCHEMBL9021094 | 0.81 | NLRP3 (0.41) | NLRP3GAAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL439922 | 0.79 | NLRP3 (0.52) | KCNQ2KCNQ3KCNQ4KCNQ5GPR35 | |
| SCHEMBL29646429 | 0.79 | NLRP3 (0.52) | KCNQ2KCNQ3KCNQ4KCNQ5GPR35 | |
| SCHEMBL9021409 | 0.78 | NLRP3 (0.39) | KCNQ2KCNQ3KCNQ4KCNQ5NLRP3 | |
| SCHEMBL11500164 | 0.76 | NLRP3 (0.44) | NLRP3GAAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL7976076 | 0.76 | NLRP3 (0.60) | NLRP3GAAALDH1A1L3MBTL1KDM4E | |
| SCHEMBL7507035 | 0.76 | NLRP3 (0.52) | KCNQ2KCNQ3KCNQ4KCNQ5GPR35 | |
| SCHEMBL4826533 | 0.76 | NLRP3 (0.51) | KCNQ2KCNQ3KCNQ4KCNQ5NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | KCNQ2 1134/4885KCNQ3 1511/4885KCNQ4 1412/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | KCNQ2 1134/4885KCNQ3 1511/4885KCNQ4 1412/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | KCNQ2 1134/4885KCNQ3 1511/4885KCNQ4 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.